METHODS OF ADMINISTERING SYNTHETIC TRITERPENOIDS
Provided are methods of administering synthetic tri terpenoids, such as bardoxolone methyl or omaveloxolone, to a patient in need thereof while avoiding adverse drug interactions with cytochrome P450 3A4 (CYP3A4) modulators. Such treatment methods comprise avoiding, contraindicating, or discontinuing concomitant use or co-administration of a cytochrome P450 3A4 modulator.
1 . A method of treating a patient having Friedreich's ataxia with a compound of the formula:
or a pharmaceutically acceptable salt or prodrug thereof;
the method comprising administering a therapeutically effective amount of the compound to the patient, wherein the patient is not currently taking a CYP3A4 modulator.
2 . The method of claim 2 ,
comprising (i) determining or having determined whether a patient is currently being administered a CYP3A4 modulator; and (ii) selecting or having selected the patient for treatment with the compound if the patient is not currently being administered a CYP3A4 modulator.
3 . (canceled)
4 . The method of claim 1 ,
wherein the patient has discontinued concomitant use of a CYP3A4 modulator.
5 - 7 . (canceled)
8 . The method of claim 1 , wherein the administration of a CYP3A4 modulator is avoided during administration of the compound.
9 . The method of claim 1 , wherein administration of the CYP3A4 modulator is discontinued prior to starting administration of the compound.
10 - 14 . (canceled)
15 . The method of claim 9 , wherein
the CYP3A4 modulator is discontinued at least 1 week prior to starting administration of the compound.
16 . The method of claim 1 ,
wherein the CYP3A4 modulator is a strong inhibitor of CYP3A4.
17 . The method of claim 1 ,
wherein the CYP3A4 modulator is a moderate inhibitor of CYP3A4.
18 . The method of claim 1 ,
wherein the CYP3A4 modulator is a moderate activator of CYP3A4.
19 . The method of claim 1 ,
wherein the CYP3A4 modulator is a strong activator of CYP3A4.
20 . The method of claim 1 ,
wherein the CYP3A4 modulator is itraconazole, clarithromycin, indinavir, nefazodone, saquinavir, suboxone, telithromycin, erythromycin, diltiazem, ketoconazole, ritonavir, goldenseal, aprepitant, erythromycin, fluconazole, grapefruit, verapamil, diltiazem, a barbiturate, carbamazepine, efavirenz, modafinil, nevirapine, oxcarbazepine, pioglitazone, rifavutin, troglitazone, phenobarbital, phenytoin, rifampicin, St. John's Wort, or a glucocorticoid.
21 - 49 . (canceled)
50 . The method of claim 1 ,
wherein the patient does not have an elevated BNP level.
51 . The method of claim 50 , wherein the patient has a BNP level less than or equal to 200 pg/mL.
52 - 152 . (canceled)
153 . The method of claim 1 , wherein at least a portion of the compound is present as a polymorphic form having an X-ray powder diffraction pattern (CuKα) comprising a halo peak at about 14° 2θ.
154 . The method of claim 153 , wherein the X-ray powder diffraction pattern (CuKα) further comprises a shoulder peak at about 8° 2θ.
155 . The method of claim 153 , wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. 5 .
156 . The method of claim 153 , further having a T g from about 150° C. to about 155° C.
157 . The method of claim 156 , further having a T g of about 153° C.
158 . The method of claim 156 , further having a T g of about 150° C.
159 . The method of claim 153 , further having a differential scanning calorimetry (DSC) curve comprising an endotherm centered from about 150° C. to about 155° C.
160 . The method of claim 159 , wherein the endotherm is centered at about 153° C.
161 . The method of claim 159 , wherein the endotherm is centered at about 150° C.
162 . The method of claim 153 , having a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 6 .
163 . The method of claim 1 , wherein at least a portion of the compound is present as a polymorphic form having a solvate having an X-ray powder diffraction pattern (CuKα) comprising significant peaks at about 5.6, 7.0, 10.6, 12.7, and 14.6° 2θ.
164 . The method of claim 163 , wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. 7 , top pattern.
165 . The method of claim 1 , wherein at least a portion of the compound is present as a polymorphic form having a solvate having an X-ray powder diffraction pattern (CuKα) comprising significant peaks at about 7.0, 7.8, 8.6, 11.9, 13.9 (double peak), 14.2, and 16.0° 2θ.
166 . The method of claim 165 , wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. 7 , second pattern from top.
167 . The method of claim 1 , wherein at least a portion of the compound is present as a polymorphic form having an acetonitrile hemisolvate having an X-ray powder diffraction pattern (CuKα) comprising significant peaks at about 7.5, 11.4, 15.6, and 16.6° 2θ.
168 . The method of claim 167 , wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. 7 , second pattern from bottom.
169 . The method of claim 167 , further having a T g of about 196° C.
170 . The method of claim 167 , further having a differential scanning calorimetry (DSC) curve comprising an endotherm centered at about 196° C.
171 . The method of claim 167 , having a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 8 .
172 . The method of claim 1 , wherein at least a portion of the compound is present as a polymorphic form having a solvate having an X-ray powder diffraction pattern (CuKα) comprising significant peaks at about 6.8, 9.3, 9.5, 10.5, 13.6, and 15.6° 2θ.
173 . The method of claim 172 , wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. 7 , bottom pattern.
174 . The method of claim 1 , wherein at least a portion of the compound is present as a crystalline polymorphic form having an X-ray powder diffraction pattern (CuKα) comprising peaks at about 10.601, 11.638, 12.121, 13.021, 13,435, 15.418, 15.760, 17.830, 18.753, and 19.671° 2θ.
175 . The method of claim 174 , wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. 9 .
176 . The method of claim 174 , wherein the melting point is about 181.98° C.
177 . The method of claim 174 , having a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 10 .
178 . The method of claim 1 , wherein at least a portion of the compound is present as a crystalline polymorphic form having an X-ray powder diffraction pattern (CuKα) comprising peaks at about 7.552, 10.339, 11.159, 12.107, 14.729, 15.329, 15.857, 16.824, 17.994, 18.344, 19.444, 19.764, 20.801, and 22.414° 2θ.
179 . The method of claim 178 , wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. 11 .
180 . The method of claim 178 , wherein the melting point is about 250.100° C.
181 . The method of claim 178 , having a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 12 .
182 . The method of claim 1 , wherein the compound is administered in a single dose per day.
183 - 184 . (canceled)
185 . The method of claim 1 , wherein the therapeutically effective amount is a daily dose of from about 25 mg to about 500 mg.
186 . (canceled)
187 . The method of claim 185 , wherein the daily dose is about 150 mg.
188 - 191 . (canceled)
192 . The method of claim 1 , wherein the therapeutically effective amount is a daily dose of 3-100 mg of compound per kg of body weight.
193 - 198 . (canceled)
199 . The method claim 1 , wherein the compound is administered orally.
200 - 203 . (canceled)